Voyager Therapeutics (VYGR) Capital Expenditures (2014 - 2026)

Voyager Therapeutics has disclosed Capital Expenditures across 13 years of filings, most recently posting $14000.0 for Q1 2026.

• Capital Expenditures for Q1 2026 came in at $14000.0, down 97.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.0 million (down 4.22% YoY), and the FY2025 annual result was $2.6 million, down 26.27% from the prior year.
• Capital Expenditures came in at $14000.0 for Q1 2026 at Voyager Therapeutics, down from $626000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $2.1 million in Q1 2024 to a low of $14000.0 in Q1 2026.
• The 5-year median for Capital Expenditures is $658000.0 (2025), against an average of $698705.9.
• Across the five-year window, Capital Expenditures soared 1241.18% in 2022 and plunged 97.87% in 2026, its largest moves.
• Voyager Therapeutics' Capital Expenditures stood at $933000.0 in 2022, then slipped by 19.08% to $755000.0 in 2023, then sank by 79.47% to $155000.0 in 2024, then surged by 303.87% to $626000.0 in 2025, then tumbled by 97.76% to $14000.0 in 2026.
• The last three Capital Expenditures figures came in at $14000.0 (Q1 2026), $626000.0 (Q4 2025), and $207000.0 (Q3 2025), per Business Quant data.